Display options
Cite
Woodworth GF, Dunn GP, Nance EA, et al. Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol. 2014;4:126doi: 10.3389/fonc.2014.00126.
Woodworth, G. F., Dunn, G. P., Nance, E. A., Hanes, J., & Brem, H. (2014). Emerging insights into barriers to effective brain tumor therapeutics. Frontiers in oncology, 4126. https://doi.org/10.3389/fonc.2014.00126
Woodworth, Graeme F, et al. "Emerging insights into barriers to effective brain tumor therapeutics." Frontiers in oncology vol. 4 (2014): 126. doi: https://doi.org/10.3389/fonc.2014.00126
Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H. Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol. 2014 Jul 21;4:126. doi: 10.3389/fonc.2014.00126. eCollection 2014. PMID: 25101239; PMCID: PMC4104487.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2014 Jul 21;4:126. doi: 10.3389/fonc.2014.00126. eCollection 2014.

Emerging insights into barriers to effective brain tumor therapeutics.

Frontiers in oncology

Graeme F Woodworth, Gavin P Dunn, Elizabeth A Nance, Justin Hanes, Henry Brem

Affiliations

  1. Department of Neurosurgery, University of Maryland School of Medicine , Baltimore, MD , USA ; Department of Anatomy and Neurobiology, University of Maryland School of Medicine , Baltimore, MD , USA.
  2. Department of Neurosurgery, Pathology and Immunology, Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine , St. Louis, MO , USA.
  3. Center for Nanomedicine, Johns Hopkins University School of Medicine , Baltimore, MD , USA.
  4. Center for Nanomedicine, Johns Hopkins University School of Medicine , Baltimore, MD , USA ; Department of Ophthalmology, Johns Hopkins University School of Medicine , Baltimore, MD , USA ; Department of Neurosurgery, Johns Hopkins University School of Medicine , Baltimore, MD , USA.
  5. Department of Neurosurgery, Johns Hopkins University School of Medicine , Baltimore, MD , USA.

PMID: 25101239 PMCID: PMC4104487 DOI: 10.3389/fonc.2014.00126

Abstract

There is great promise that ongoing advances in the delivery of therapeutics to the central nervous system (CNS) combined with rapidly expanding knowledge of brain tumor patho-biology will provide new, more effective therapies. Brain tumors that form from brain cells, as opposed to those that come from other parts of the body, rarely metastasize outside of the CNS. Instead, the tumor cells invade deep into the brain itself, causing disruption in brain circuits, blood vessel and blood flow changes, and tissue swelling. Patients with the most common and deadly form, glioblastoma (GBM) rarely live more than 2 years even with the most aggressive treatments and often with devastating neurological consequences. Current treatments include maximal safe surgical removal or biopsy followed by radiation and chemotherapy to address the residual tumor mass and invading tumor cells. However, delivering effective and sustained treatments to these invading cells without damaging healthy brain tissue is a major challenge and focus of the emerging fields of nanomedicine and viral and cell-based therapies. New treatment strategies, particularly those directed against the invasive component of this devastating CNS disease, are sorely needed. In this review, we (1) discuss the history and evolution of treatments for GBM, (2) define and explore three critical barriers to improving therapeutic delivery to invasive brain tumors, specifically, the neuro-vascular unit as it relates to the blood brain barrier, the extra-cellular space in regard to the brain penetration barrier, and the tumor genetic heterogeneity and instability in association with the treatment efficacy barrier, and (3) identify promising new therapeutic delivery approaches that have the potential to address these barriers and create sustained, meaningful efficacy against GBM.

Keywords: advanced therapeutics; blood brain barrier; brain cancer; drug delivery; glioblastoma; immunotherapy; nanomedicine; nanotechnology

References

  1. Biomaterials. 2007 Nov;28(33):4947-67 - PubMed
  2. Brain Res. 1988 Oct 11;462(1):1-9 - PubMed
  3. J Physiol. 1979 Nov;296:66P - PubMed
  4. Mol Interv. 2003 Mar;3(2):90-105, 51 - PubMed
  5. Gene Ther. 2012 Feb;19(2):189-200 - PubMed
  6. Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 - PubMed
  7. Science. 2011 Aug 19;333(6045):1039-43 - PubMed
  8. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401 - PubMed
  9. J Clin Oncol. 2009 Oct 1;27(28):4733-40 - PubMed
  10. Cancer Cell. 2011 Dec 13;20(6):810-7 - PubMed
  11. Oncol Res. 2007;16(8):351-9 - PubMed
  12. FASEB J. 2005 Mar;19(3):425-7 - PubMed
  13. Cancer Res. 2009 Dec 1;69(23):8932-40 - PubMed
  14. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15155-60 - PubMed
  15. Fluids Barriers CNS. 2012 Apr 30;9(1):10 - PubMed
  16. Cancer Res. 2004 Jul 15;64(14):4973-9 - PubMed
  17. Cancer Sci. 2009 Aug;100(8):1451-9 - PubMed
  18. Adv Drug Deliv Rev. 2012 May 15;64(7):590-7 - PubMed
  19. J Neurosurg. 2011 Mar;114(3):624-32 - PubMed
  20. Pharm Res. 1997 Mar;14(3):325-8 - PubMed
  21. Am Pract Dig Treat. 1961 Mar;12:169-74 - PubMed
  22. Am J Clin Oncol. 2005 Feb;28(1):81-90 - PubMed
  23. Science. 2007 Oct 12;318(5848):287-90 - PubMed
  24. Eur J Paediatr Neurol. 2012 May;16(3):279-84 - PubMed
  25. Clin Cancer Res. 2011 Mar 15;17(6):1603-15 - PubMed
  26. J Nucl Med. 1990 Jun;31(6):969-71 - PubMed
  27. PLoS One. 2011;6(11):e26100 - PubMed
  28. J Neurosurg. 2010 Aug;113(2):301-9 - PubMed
  29. Lung Cancer. 2009 Feb;63(2):259-63 - PubMed
  30. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2820-4 - PubMed
  31. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  32. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9 - PubMed
  33. Biomaterials. 2012 Aug;33(23):5768-75 - PubMed
  34. J Microencapsul. 2008 Dec;25(8):561-8 - PubMed
  35. J Control Release. 2012 Jul 20;161(2):290-306 - PubMed
  36. Surg Forum. 1974;25(0):462-4 - PubMed
  37. World Neurosurg. 2012 Jan;77(1):130-4 - PubMed
  38. Sci Transl Med. 2011 May 25;3(84):84ra44 - PubMed
  39. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6 - PubMed
  40. Oncogene. 2002 Dec 5;21(55):8404-13 - PubMed
  41. Sci Transl Med. 2012 Feb 22;4(122):122ra21 - PubMed
  42. Int J Cancer. 2002 Mar 20;98(3):362-9 - PubMed
  43. Nat Med. 2007 Oct;13(10):1173-5 - PubMed
  44. Nature. 2010 Jan 21;463(7279):318-25 - PubMed
  45. Neuro Oncol. 2003 Apr;5(2):96-103 - PubMed
  46. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1799-803 - PubMed
  47. Cancer Res. 2012 Jul 15;72(14):3652-63 - PubMed
  48. Science. 2008 Sep 26;321(5897):1807-12 - PubMed
  49. Cancer Res. 2008 Jul 15;68(14):5955-64 - PubMed
  50. N Engl J Med. 2005 Mar 10;352(10):997-1003 - PubMed
  51. J Immunol. 1992 Jul 1;149(1):260-8 - PubMed
  52. Hum Gene Ther. 2004 Apr;15(4):339-50 - PubMed
  53. Neuro Oncol. 2010 Aug;12(8):871-81 - PubMed
  54. Yale J Biol Med. 1993 Jul-Aug;66(4):277-314 - PubMed
  55. Nature. 1976 Oct 28;263(5580):797-800 - PubMed
  56. J Neurooncol. 2003 Oct;65(1):77-85 - PubMed
  57. Adv Drug Deliv Rev. 2009 Nov 12;61(13):1117-20 - PubMed
  58. Nat Rev Clin Oncol. 2009 Apr;6(4):229-36 - PubMed
  59. Brain Res. 1991 Sep 20;559(2):276-82 - PubMed
  60. BMC Genomics. 2008 Jan 29;9:54 - PubMed
  61. Sci Transl Med. 2012 Aug 15;4(147):147ra111 - PubMed
  62. Nano Lett. 2006 Apr;6(4):669-76 - PubMed
  63. Oncogene. 1998 Apr 30;16(17):2259-64 - PubMed
  64. J Neurosurg. 2011 Jun;114(6):1654-61 - PubMed
  65. Radiat Res. 2005 May;163(5):544-51 - PubMed
  66. Neurology. 2009 Oct 13;73(15):1200-6 - PubMed
  67. Cancer. 2001 Oct 1;92(7):1936-42 - PubMed
  68. Neurosurgery. 2012 Feb;70(2):361-70 - PubMed
  69. Mol Ther. 2009 Dec;17(12):2088-95 - PubMed
  70. Neurology. 2010 Apr 13;74(15):1239-41 - PubMed
  71. J Neurooncol. 2004 Nov;70(2):217-28 - PubMed
  72. Br J Cancer. 2000 Nov;83(10):1281-6 - PubMed
  73. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6 - PubMed
  74. Hum Gene Ther. 2011 Nov;22(11):1365-77 - PubMed
  75. PLoS One. 2011;6(5):e19868 - PubMed
  76. Curr Gene Ther. 2009 Oct;9(5):422-7 - PubMed
  77. J Lancet. 1961 Feb;81:46-53 - PubMed
  78. Neurol Clin. 1985 Nov;3(4):711-28 - PubMed
  79. Nature. 1984 Dec 13-19;312(5995):649-51 - PubMed
  80. J Exp Med. 1975 Feb 1;141(2):427-39 - PubMed
  81. Sci Transl Med. 2012 Apr 18;4(130):130ra46 - PubMed
  82. J Neurooncol. 1983;1(4):283-91 - PubMed
  83. Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 - PubMed
  84. Cancer Sci. 2012 Aug;103(8):1489-92 - PubMed
  85. Neurosurgery. 2006 Apr;58(4):701-9; discussion 701-9 - PubMed
  86. Cancer Res. 1999 Feb 1;59(3):669-75 - PubMed
  87. Lancet Oncol. 2006 Sep;7(9):778-80 - PubMed
  88. NeuroRx. 2005 Jan;2(1):1-2 - PubMed
  89. Curr Mol Med. 2009 Jun;9(5):580-90 - PubMed
  90. Clin Cancer Res. 2011 Sep 1;17(17):5765-73 - PubMed
  91. J Control Release. 2007 Nov 6;123(2):172-8 - PubMed
  92. Nat Rev Cancer. 2010 May;10(5):319-31 - PubMed
  93. Nat Rev Drug Discov. 2002 Feb;1(2):131-9 - PubMed
  94. Physiol Rev. 2008 Oct;88(4):1277-340 - PubMed
  95. PLoS One. 2010 Jun 30;5(6):e11323 - PubMed
  96. PLoS One. 2012;7(2):e30804 - PubMed
  97. Can J Neurol Sci. 2007 Nov;34(4):402-10 - PubMed
  98. Radiother Oncol. 2002 Sep;64(3):259-73 - PubMed
  99. Mol Pharm. 2011 Dec 5;8(6):1993 - PubMed
  100. Curr Cancer Drug Targets. 2010 Dec 15;: - PubMed
  101. Neuro Oncol. 2003 Apr;5(2):79-88 - PubMed
  102. J Clin Oncol. 2010 Nov 1;28(31):4722-9 - PubMed
  103. Oncogene. 1998 Jan 22;16(3):321-6 - PubMed
  104. Neurosci Lett. 2009 Mar 13;452(2):114-8 - PubMed
  105. Cell. 2013 Oct 10;155(2):462-77 - PubMed
  106. Mol Cancer Ther. 2012 Jun;11(6):1289-99 - PubMed
  107. Cancer Gene Ther. 2000 Nov;7(11):1437-47 - PubMed
  108. J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 - PubMed
  109. Prog Brain Res. 2000;125:129-54 - PubMed
  110. Neuro Oncol. 2009 Jun;11(3):281-91 - PubMed
  111. N Engl J Med. 2014 Feb 20;370(8):699-708 - PubMed
  112. Biophys J. 2008 Aug;95(3):1382-92 - PubMed
  113. NeuroRx. 2005 Jan;2(1):3-14 - PubMed
  114. Glia. 2003 Apr 1;42(1):77-88 - PubMed
  115. J Neurosurg. 1961 Sep;18:636-44 - PubMed
  116. Methods Enzymol. 2009;465:349-62 - PubMed
  117. Sci Transl Med. 2012 Aug 29;4(149):149ra119 - PubMed
  118. J Neurooncol. 2007 Apr;82(2):151-61 - PubMed
  119. J Neurosurg. 2003 Aug;99(2):297-303 - PubMed
  120. Br J Cancer. 2012 Jun 5;106(12):1934-9 - PubMed
  121. Neuro Oncol. 1999 Oct;1(4):268-74 - PubMed
  122. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 - PubMed
  123. J Neurol Sci. 1970 Mar;10(3):215-39 - PubMed
  124. Hum Gene Ther. 2000 Nov 20;11(17):2389-401 - PubMed
  125. Pharm Res. 1999 Oct;16(10):1564-9 - PubMed
  126. Ann Neurol. 1983 Jan;13(1):28-31 - PubMed
  127. N Engl J Med. 2008 Jul 31;359(5):492-507 - PubMed
  128. J Vis Exp. 2010 Dec 15;(46): - PubMed
  129. Med Hypotheses. 2011 Jun;76(6):884-6 - PubMed
  130. Oncology. 2010;78(2):103-14 - PubMed
  131. Neuro Oncol. 2010 Jun;12(6):520-7 - PubMed
  132. Lancet. 2002 Mar 23;359(9311):1011-8 - PubMed
  133. Neurosurgery. 2000 Dec;47(6):1391-8; discussion 1398-9 - PubMed
  134. Drug Deliv. 2004 May-Jun;11(3):169-83 - PubMed
  135. Clin Cancer Res. 2009 Jun 1;15(11):3697-704 - PubMed
  136. Cancer Res. 2001 Feb 1;61(3):842-7 - PubMed
  137. Nat Rev Clin Oncol. 2010 Nov;7(11):653-64 - PubMed
  138. J Neurosurg. 1992 Apr;76(4):640-7 - PubMed
  139. J Comb Chem. 1999 Jan;1(1):55-68 - PubMed
  140. Nature. 2008 Oct 23;455(7216):1061-8 - PubMed
  141. Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7 - PubMed
  142. J Neurooncol. 2011 Jun;103(2):343-51 - PubMed
  143. Neuro Oncol. 2010 May;12(5):508-16 - PubMed
  144. Cancer Res. 1987 Aug 15;47(16):4432-43 - PubMed
  145. Brain Pathol. 1992 Oct;2(4):269-76 - PubMed
  146. Pharm Res. 1997 Jun;14(6):820-6 - PubMed
  147. Biomaterials. 2009 Apr;30(12):2302-18 - PubMed
  148. Neurochem Int. 2004 Sep;45(4):545-52 - PubMed
  149. Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15172-7 - PubMed
  150. J Neurosurg. 2003 Nov;99(5):893-8 - PubMed
  151. Cancer Cell. 2006 Mar;9(3):157-73 - PubMed
  152. Neurol Med Chir (Tokyo). 1990 Aug;30(8):582-90 - PubMed
  153. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5567-72 - PubMed
  154. Mol Neurobiol. 2004 Feb;29(1):61-71 - PubMed
  155. Neurosurgery. 1980 Jun;6(6):675-85 - PubMed
  156. J Neurosurg. 1999 Feb;90(2):300-5 - PubMed
  157. J Neurosurg. 1978 Sep;49(3):333-43 - PubMed
  158. Crit Rev Oncol Hematol. 2011 Aug;79(2):127-34 - PubMed
  159. N Engl J Med. 2009 Feb 19;360(8):765-73 - PubMed
  160. Neurosurg Focus. 2013 Feb;34(2):E9 - PubMed
  161. Nat Mater. 2003 Nov;2(11):767-72 - PubMed
  162. Neurosurgery. 1998 Aug;43(2):235-40; discussion 240-1 - PubMed
  163. Mol Pharm. 2011 Oct 3;8(5):1515-24 - PubMed
  164. Anticancer Res. 2000 May-Jun;20(3A):1337-42 - PubMed
  165. Lancet. 1995 Apr 22;345(8956):1008-12 - PubMed
  166. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  167. J Neurooncol. 2001 Jul;53(3):267-71 - PubMed
  168. J Neurosci. 2008 Feb 20;28(8):1882-93 - PubMed
  169. J Cereb Blood Flow Metab. 2007 Jan;27(1):43-56 - PubMed
  170. Clin Cancer Res. 2011 Oct 1;17(19):6192-205 - PubMed
  171. FASEB J. 2010 Mar;24(3):778-87 - PubMed
  172. Eur J Pharm Biopharm. 2010 Feb;74(2):157-63 - PubMed
  173. Brain Tumor Pathol. 2004;21(2):53-6 - PubMed
  174. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2426-31 - PubMed
  175. J Neurooncol. 2003 May;62(3):297-303 - PubMed
  176. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  177. Pain Physician. 2011 May-Jun;14(3):219-48 - PubMed
  178. J Control Release. 2001 Jul 6;74(1-3):63-7 - PubMed
  179. N Engl J Med. 2014 Feb 20;370(8):709-22 - PubMed

Publication Types

Grant support